<DOC>
	<DOCNO>NCT00174343</DOCNO>
	<brief_summary>To evaluate clinical pathologic response rate follow primary hormonal therapy exemestane ( AromasinÂ® )</brief_summary>
	<brief_title>Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Postmenopausal patient unilateral breast cancer T2 T4 , N01 , M0 , non inflammatory , operable , hormonal receptor positive Patients bilateral breast cancer T4d , inflammatory , non operable , hormonal receptor negative</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>